Putative Biomarkers and Targets of Estrogen Receptor Negative Human Breast Cancer
AbstractBreast cancer is a progressive and potentially fatal disease that affects women of all ages. Like all progressive diseases, early and reliable diagnosis is the key for successful treatment and annihilation. Biomarkers serve as indicators of pathological, physiological, or pharmacological processes. Her2/neu, CA15.3, estrogen receptor (ER), progesterone receptor (PR), and cytokeratins are biomarkers that have been approved by the Food and Drug Administration for disease diagnosis, prognosis, and therapy selection. The structural and functional complexity of protein biomarkers and the heterogeneity of the breast cancer pathology present challenges to the scientific community. Here we review estrogen receptor-related putative breast cancer biomarkers, including those of putative breast cancer stem cells, a minor population of estrogen receptor negative tumor cells that retain the stem cell property of self renewal. We also review a few promising cytoskeleton targets for ER alpha negative breast cancer.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Sahab, Z.J.; Man, Y.-G.; Byers, S.W.; Sang, Q.-X. Putative Biomarkers and Targets of Estrogen Receptor Negative Human Breast Cancer. Int. J. Mol. Sci. 2011, 12, 4504-4521.
Sahab ZJ, Man Y-G, Byers SW, Sang Q-X. Putative Biomarkers and Targets of Estrogen Receptor Negative Human Breast Cancer. International Journal of Molecular Sciences. 2011; 12(7):4504-4521.Chicago/Turabian Style
Sahab, Ziad J.; Man, Yan-Gao; Byers, Stephen W.; Sang, Qing-Xiang A. 2011. "Putative Biomarkers and Targets of Estrogen Receptor Negative Human Breast Cancer." Int. J. Mol. Sci. 12, no. 7: 4504-4521.